

# High Blood Pressure and Cardiovascular Disease

Flávio D. Fuchs, Paul K. Whelton

**Abstract**—Fragmented investigation has masked the overall picture for causes of cardiovascular disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with the strongest evidence for causation and it has a high prevalence of exposure. Biologically, normal levels of BP are considerably lower than what has typically been characterized as normal in research and clinical practice. We propose that CVD is primarily caused by a right-sided shift in the population distribution of BP. Our view that BP is the predominant risk factor for CVD is based on conceptual postulates that have been tested in observational investigations and clinical trials. Large cohort studies have demonstrated that high BP is an important risk factor for heart failure, atrial fibrillation, chronic kidney disease, heart valve diseases, aortic syndromes, and dementia, in addition to coronary heart disease and stroke. In multivariate modeling, the presumed attributable risk of high BP for stroke and coronary heart disease has increased steadily with progressive use of lower values for normal BP. Meta-analysis of BP-lowering randomized controlled trials has demonstrated a benefit which is almost identical to that predicted from BP risk relationships in cohort studies. Prevention of age-related increases in BP would, in large part, reduce the vascular consequences usually attributed to aging, and together with intensive treatment of established hypertension would eliminate a large proportion of the population burden of BP-related CVD.

High blood pressure (BP), cigarette smoking, diabetes mellitus, and lipid abnormalities are major modifiable risk factors for cardiovascular disease (CVD). Among these, high BP is associated with the strongest evidence for causation and has a high prevalence of exposure. However, there is considerable evidence that a biologically normal level of BP in humans is considerably lower than what has been traditionally employed in clinical practice and research, leading to an underrepresentation of the role that BP plays as a risk factor for CVD. We propose the following integrated theory for CVD causation that is supported by a robust body of coherent and consistent evidence: CVD in humans is primarily caused by a right-sided shift in the distribution of BP.

Theories abound in the current era of social networks, but few fulfill the basic requirements for causality. Scientific theories are most credible because they are structured and subject to refutation by systematic observation and experimental hypothesis testing.<sup>1</sup> Our theory fulfills virtually all of the criteria for causality proposed by Bradford Hill.<sup>2</sup>

## Shift of BP Distribution in Humans: Uncovering a Selection Bias

At the end of the 19th century, Osler<sup>3</sup> did not mention the risks of high BP in his classic *The Principles and Practice of Medicine* textbook because, at that time, there was no practical way to measure BP using a noninvasive technique. Shortly after the development<sup>4,5</sup> and dissemination of noninvasive methods for BP measurement physicians and actuaries deduced that high BP could be a cause of disease, especially CVD events.<sup>6,7</sup> In 1913, Janeway<sup>7</sup> study of 7872

patients led him to conclude that an average BP above 160 mm Hg was pathological.

Despite the merits of early BP-CVD association reports, they compared the risk of CVD in adults identified as having a very high level of BP with the corresponding risk in counterparts with a lower but still high BP. The pioneers of BP measurement could not know that nearly all humans, including most of those in the lower BP category, had a level of BP above what is biologically normal and desirable. It took several decades before BP was measured in groups of humans with a true biologically normal BP because they were living in isolated unacculturated societies. Investigators discovered that almost all of those studied had an average BP that was substantially lower than the corresponding levels noted in studies that had been conducted in acculturated societies.<sup>8–11</sup>

There are potentially confounding differences between people living in acculturated societies and their counterparts living in isolated unacculturated societies. Most of these confounding variables were, however, controlled in a seminal study of 2 Amazonian tribes who had a similar background and cultural habits, with the exception of a difference in sodium intake.<sup>8</sup> The Mundurucus, whose lifestyle was influenced by the Franciscans, had incorporated salt into their diet as a means to preserve and season their food. In contrast, the Carajás had little contact with Westerners and consumed almost no salt. Average BP during adult life increased with rising age in the Mundurucus but not in the Carajás (Figure 1), whose mean systolic BP (SBP) and diastolic BP (DBP) remained about 110 and 60 mm Hg, respectively, throughout their adult lifespan.

From the Division of Cardiology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil (F.D.F.); and Departments of Epidemiology and Medicine, Tulane University, New Orleans, LA (P.K.W.).


Correspondence to Paul K. Whelton, 1440 Canal St, Room 2015, New Orleans, LA 70112. Email pkwhelton@gmail.com

(*Hypertension*. 2020;75:285–292. DOI: 10.1161/HYPERTENSIONAHA.119.14240.)

© 2019 American Heart Association, Inc.

*Hypertension* is available at <https://www.ahajournals.org/journal/hyp>


DOI: 10.1161/HYPERTENSIONAHA.119.14240



**Figure 1.** Blood pressure (BP) for men by age in Mundurucus and Carajás Indians, showing a rise with aging in the acculturated Mundurucus but not in the unacculturated Carajás. Reprinted from *The Lancet* (Lowenstein<sup>9</sup>) with permission. Copyright © 1961, Elsevier.

Another isolated society in Brazil, the Yanomamo Indians, with very limited access to salt also demonstrated little if any rise in BP with aging.<sup>10</sup> In addition to excreting very little sodium in their urine, they had high levels of plasma renin activity and aldosterone. These findings suggest biologically normal values of BP, renin activity, and aldosterone are very different compared with the relatively high levels of BP and low levels of plasma renin activity and aldosterone identified in acculturated societies, where there is exposure to high levels of dietary sodium. Animal model studies, population studies, and clinical trials provide evidence supporting the central role of excessive sodium consumption in causing age-related increases of BP.<sup>12</sup>

The consequences of 2 definitions for identification of an abnormally high BP are depicted in Figure 2. The left-hand panel depicts the rightward shift of SBP and DBP that occurs with acculturation. The shaded area in the distribution for unacculturated populations identifies high BP using a definition (SBP  $\geq 120$  mm Hg or DBP  $\geq 70$  mm Hg) is based on the BP distribution in observational studies. The corresponding shaded area in the distribution for acculturated populations is based on a definition of high BP (SBP  $\geq 140$  mm Hg or DBP  $\geq 90$  mm Hg) that has traditionally been used in acculturated populations. The shaded areas in the right-hand panel identifies high BP in acculturated societies using the SBP 120 mm Hg and DBP  $\geq 70$  mm Hg cut points.



**Figure 2.** Left part depicts distribution of systolic and diastolic blood pressure (BP) in unacculturated and acculturated populations. Shaded areas identify distribution of a high BP definition (systolic BP  $\geq 120$  mm Hg or diastolic BP  $\geq 70$  mm Hg) for adults in unacculturated societies and for their counterparts living in acculturated societies using the traditional definition for diagnosis of hypertension (systolic BP  $\geq 140$  mm Hg or diastolic BP  $\geq 90$  mm Hg). Shaded areas in the right part highlight distribution of high systolic and diastolic BP applying the definition used for high BP in unacculturated societies (SBP  $\geq 120$  mm Hg or diastolic BP  $\geq 70$  mm Hg).


Around 70% of those living in acculturated societies would be at higher risk of developing CVD according these values. Using the cut points proposed for diagnosis of hypertension in the 2017 American College of Cardiology/American Heart Association BP guideline (SBP  $\geq 130$  mmHg or DBP  $\geq 80$  mmHg),<sup>13</sup> around 63% of adults aged 45 to 75 years in the United States and 55% in China have hypertension.<sup>14</sup>

In recent decades, a leftward shift in the distribution of BP has been identified in high-income countries.<sup>15</sup> As expected, this downward shift in BP has been accompanied by a reduction in the incidence of CVD. The absolute number of individuals with hypertension in the world, however, has increased due to a rightward shift in the distribution of BP in low- and middle-income countries.<sup>15</sup>

### Evidence From Cohort Studies

In an early cohort study, Keith et al<sup>16</sup> reported on BP-related risks, stratified by BP levels, symptoms, ECG abnormalities, albuminuria/hematuria, and optic fundi abnormalities. The mortality rate was proportional to severity of illness, being  $>80\%$  over 1 year for participants who had BP resistant to treatment, bad general condition, an abnormal ECG, albuminuria, hematuria, and optical edema (characterized as class IV). Despite this and other observational reports published in the first half of the 20th century that suggested high BP caused CVD, many opinion leaders believed high BP was an inconsequential finding and use of the term benign essential hypertension was commonplace. White was in the group of influential leaders who believed high BP was a physiological compensatory mechanism and should not be manipulated by treatment.<sup>17</sup>

In a series of seminal reports, the Prospective Studies Collaboration pooled data from many cohort studies and accounted for the effects of regression dilution bias to generate precise estimates of the relationship between BP and CVD. Their most important report<sup>18</sup> was based on experience in 61 cohort studies that provided 12.7 million person-years of risk experience (56 000 deaths from coronary heart disease [CHD] and stroke). The risk of CVD increased steadily with progressively higher levels of baseline SBP and DBP, above a usual SBP and DBP of 115 and 75 mmHg, respectively. For a 20 mmHg higher level of SBP and 10 mmHg higher level of DBP the risk of CVD was 2-fold higher (Figure 3, left, with log-transformed vertical axis). The corresponding pattern for



**Figure 3.** Log transformed (left) and untransformed (right) absolute risk of coronary heart disease or stroke in adults, by systolic and diastolic blood pressure, stratified by age. Reprinted from *The Lancet* (Lewington et al<sup>18</sup>) with permission, copyright © 2002 Elsevier; and reprinted from Fuchs<sup>19</sup> with permission, copyright © 2018, Springer International Publishing.

BP-related absolute risk of CVD (Figure 3, right), revealed an exponential association between increased BP and risk for CHD and stroke. It identified a relatively small increment in absolute risk of CVD with increasing BP levels at lower BP values and at younger age, which likely explains why individual studies in young and middle-aged participants have only identified a CVD risk at higher values of BP.<sup>19</sup>

Most of the early observational studies were focused on BP complications (stroke and CHD) which usually occur earlier than other BP clinical consequences and are especially prominent at higher levels of BP. At older age, stroke and CHD are accompanied by several complications that develop over a longer period of exposure to high BP, either because the target organs are more resistant or because more modest BP elevations have been present for a prolonged period of time. The complications of high BP can be classified as short- and long-term consequences (Table). Consistent observational evidence suggests high BP is the leading cause of long-term consequences such as heart failure, with and without preserved ejection fraction,<sup>20</sup> atrial fibrillation,<sup>21</sup> valvular heart disease,<sup>22,23</sup> peripheral arterial disease and aortic syndromes,<sup>24</sup> chronic kidney disease and end stage renal disease,<sup>25,26</sup> dementia,<sup>27,28</sup> and Alzheimer Disease.<sup>29</sup> Diabetes mellitus,<sup>30</sup> erectile dysfunction,<sup>31</sup> and age-related macular degeneration<sup>32</sup> are other conditions that likely have high BP as one of their causes.

### Centenarians

The primary reason that centenarians reach 100 years of age is an unusually low burden of CVD and cancer. CHD, stroke, dementia, and hypertension are less frequent in centenarians compared with individuals who die at a younger age<sup>33</sup> (Figure 4). Vascular aging is directly associated with level of BP and not inexorable. Prevention of age-related increases in BP would substantially reduce the vascular consequences usually attributed to aging. Individuals who

develop hypertension late in life are not at increased risk for CVD earlier in life.<sup>34</sup> Centenarians may be resistant to dietary sodium loads having the ability to excrete sodium in the absence of high-pressure natriuresis.


### Cartesian Evidence

Experimental studies, the highest hierarchical method for demonstration of causality, provide strong support for our theory of CVD causation. The 1967 Veterans Administration Cooperative Study Group on Antihypertensive Agents,<sup>35</sup> SHEP trial (Systolic Hypertension in the Elderly Program)<sup>36</sup> and SPRINT (Systolic Blood Pressure Intervention Trial)<sup>37</sup> are 3 of

**Table. Short-Term and Long-Term Consequences of High BP**

Short and long-term consequences
Stroke
Coronary heart disease
Heart failure
Cardiovascular death
Long-term consequences
Hypertensive cardiomyopathy
Heart failure with preserved ejection fraction
Atrial fibrillation
Valvular heart disease
Aortic syndromes
Peripheral arterial disease
Chronic kidney disease
Dementias
Diabetes mellitus
Erectile dysfunction

BP indicates blood pressure.



**Figure 4.** Disease-free age survival for cardiovascular disease (CVD), dementia, stroke, and hypertension (HTN) in controls (individuals without a familial predisposition for exceptional longevity (black line), and centenarians (color lines), stratified by age in years at death. The data demonstrate a consistent delay in onset of CVD, dementia, and stroke when HTN starts late in life. Reprinted from Andersen et al<sup>39</sup> with permission. Copyright © 2012, The Author. Published by Oxford University Press on behalf of The Gerontological Society of America.


many randomized controlled trials (RCTs) that have provided strong evidence regarding the effectiveness of BP lowering for prevention of CVD. Redefining the outcomes according to a modern paradigm, the number needed to treat to prevent one major CVD event per year in the 1967 Veterans Administration trial was only 6 patients in those with a baseline DBP averaging 115 to 129 mmHg.<sup>38</sup> Before publication of the SHEP results, many doctors believed isolated systolic hypertension was a natural and benign compensatory consequence of aging. The trial showed that chlorthalidone-based therapy reduced the incidence of stroke, the primary end point, by 36% compared with placebo.<sup>36</sup> SPRINT demonstrated that participants randomized to a SBP goal <120 mmHg (intensive treatment) had an incidence of the primary composite CVD end point that was 25% lower compared with those randomized to a SBP goal <140 mmHg (standard treatment).<sup>37</sup> There were reductions of 43% in CVD mortality and 27% in all-cause mortality. A similar benefit was demonstrated in the relatively large (N=2636) subgroup of participants 75 years or older at baseline, including those with frailty and reduced gait speed.<sup>39</sup>

High-quality meta-analyses have demonstrated the effectiveness of BP lowering for prevention of CVD. Additionally, studies have compared the observed benefit of BP reduction

in RCTs with the expected benefit based on BP as a risk factor for CVD in observational studies.<sup>40–42</sup> In a study that included 147 RCTs, Law et al<sup>40</sup> calculated the CVD risk reduction for the average active treatment versus control trial difference in SBP (10 mmHg) observed in their meta-analysis. As depicted in Figure 5, the reductions in stroke and CHD incidence rates were similar to the benefits expected on the basis of a 10 mmHg difference in SBP in the Prospective Studies Collaboration meta-analysis of observational studies. Benefit for the same difference in BP was greater for stroke, reflecting the higher risk of elevated BP for cerebral vessels compared with the coronary circulation.

A similar benefit was observed in a network meta-analysis conducted by Bundy et al.<sup>42</sup> In this study, the relative risk reduction of major CVD events in trials where the participants had been treated to a SBP target between 120 and 124 mmHg, compared with a corresponding target of 160 mmHg or higher, was 64%, which is close to the hypothetical risk reduction of 75% for a 40 mmHg SBP reduction in the Prospective Studies Collaboration meta-analysis.<sup>18</sup> The similarity between risk predicted in cohort studies and benefit demonstrated in RCTs fulfills one of the postulates of Descartes,<sup>43</sup> that is, that the sum of the angles of any triangle





**Figure 5.** Relative risk estimates of coronary heart disease (top) and stroke (bottom) for systolic blood pressure (BP) reduction of 10 mmHg or diastolic BP reduction of 5 mmHg in clinical trials meta-analysis and corresponding difference in meta-analysis of observational cohort studies. CHD indicates coronary heart disease; CV, cardiovascular; and RR, relative risk. Reprinted from Law et al<sup>40</sup> with permission. Copyright © 2009, BMJ Publishing Group Ltd.

equals 180 degrees (2 right angles). The close approximation between the observed (clinical trials) and expected (observational cohort studies) benefits of BP lowering is impressive, since the expected estimate is based on imperfect measurements of a biological parameter.

Scant experimental evidence exists for prevention of the longer term consequences of high BP. Designing trials for these end points is challenging, because they require a longer duration of treatment than is necessary to demonstrate CVD benefit. Despite this, suggestive benefit of BP lowering in RCTs exists for some of these outcomes. For example, the composite outcome of mild cognitive impairment and dementia was significantly less common during long-term follow-up in the SPRINT study.<sup>44,45</sup>

The central role of BP levels has also been demonstrated by studies where BP has risen during treatment and resulted in CVD events. Examples come from studies using celecoxib,<sup>46</sup> sibutramine,<sup>47</sup> and torcetrapib.<sup>48</sup> In contrast, prevention of CVD events by inhibitors of sodium-glucose cotransporter 2 in adults with,<sup>49,50</sup> and without diabetes mellitus<sup>51</sup> may be due, in part, to BP-lowering.

### Attributable Risks

Estimation of the high BP contribution to causation of CVD has increased progressively as the definition of hypertension and analytic techniques have evolved. Early estimates of attributable risk were 25% for CHD and 50% for stroke.<sup>52</sup> Based on the risks identified by the Prospective Studies Collaboration,<sup>18</sup> the attributable risk for BP equal or >115/75 mmHg was estimated to be 49% for CHD and 62% for stroke.<sup>53</sup> However, these estimates almost certainly understate the true contribution of high BP to development of CVD. In many of the cohort studies, residual bias in estimation is probable because the risk estimates have been based on only a few BP measurements. Vascular, cardiac, and renal damage results from an excessively high vascular load of beat-to-beat elevations in BP over long periods.<sup>19</sup> One or 2 BP measurements provide an insufficient estimate of vascular load. Other CVD risk factors, such as smoking, dyslipidemia and excess body weight, are subject to measurement error, but their estimation is much more precise compared to BP readings. More efficient methods for BP measurement, such as ambulatory BP measurement,<sup>54</sup> particularly at

nighttime,<sup>55</sup> home BP monitoring and automated office BP measurement provide more precise estimation of BP-CVD risk, including identification of risk at lower BP values compared to traditional office BP measurements.<sup>54</sup> Another reason for underestimation of BP-related risk is inclusion of intermediate consequences of high BP as causes of CVD in multivariate explanatory equations.<sup>56</sup> This is especially true for analyses that have included left ventricular hypertrophy or vascular wall thickening, but even overweight and obesity are CVD risk factors that are largely mediated by high BP.<sup>57</sup> Recognizing the potential for underestimation, other confounding risks increase concomitantly with BP, but in clinical trials the absolute risk reduction from BP-lowering accounts for nearly all of the predicted risk, leaving little residual risk to be explained by the other concomitant risks.

### What Is Missing?

In adults without CVD, a strong BP-CVD risk association has been identified at lower levels of SBP (120–139 mm Hg) and DBP (80–89 mm Hg).<sup>18</sup> Individuals within this BP range are at increased risk for development of higher levels of BP over relatively short periods of follow-up<sup>58,59</sup> and already have evidence of target organ damage.<sup>60,61</sup> Moreover, meta-analyses of event-based RCTs have shown the benefit of antihypertensive treatment in adults with CVD (secondary prevention) and an average BP within the same range.<sup>40,41</sup> Trials have also shown that low-dose pharmacotherapy in adults without CVD and an average SBP of 130–139 mm Hg or DBP  $\leq$  89 mm Hg<sup>62,63</sup> and SBP 120–139 mm Hg or DBP 80–89 mm Hg<sup>64</sup> lowers BP and prevents incident hypertension (SBP  $\geq$  140 mm Hg or DBP  $\geq$  90 mm Hg). The PREVER-Prevention trial additionally demonstrated that low-dose diuretic therapy (chlorthalidone and amiloride) in adults with a SBP 120–139 mm Hg or DBP 80–89 mm Hg prevented incident LVH estimated by ECG.<sup>64</sup>

Nonetheless, no BP-lowering trial has demonstrated prevention of CVD events in adults without CVD who have a SBP  $<$  140 mm Hg or DBP  $<$  90 mm Hg.

Despite strong evidence of a BP-lowering benefit in clinical trials and meta-analyses, direct documentation of intensive BP-lowering benefit is lacking in adults with high BP who have diabetes mellitus or a history of prior stroke. At least 2 event-based trials (one in Brazil and the other in China) are addressing this question in diabetics and one trial (in Brazil) is being conducted in stroke survivors.

### Conclusions and Perspectives

Our proposal that CVD is predominantly caused by a rightward shift in the distribution of BP is supported by coherence and factual evidence. As a theory, it is open to refutation and formulation of alternative proposals. Among the existing theories, however, ours is the one that best meets Occam's razor premise, that is, it is the hypothesis with the fewest assumptions. Other risk factors, including lipid abnormalities, cigarette smoking, physical inactivity, and dietary influences other than sodium play an important role in CVD causation. Although elevated BP has the greatest effect on population health, prevention of CVD is best achieved by a comprehensive approach aimed at improving CVD risk factors at all stages of life.

Regardless of its exact contribution, high BP is a major risk factor for development of CVD. Prevention of the age-related increase in BP would substantially reduce the vascular consequences usually attributed to aging. It is time to focus greater attention on initiatives for prevention of the typical age-related increase in BP in addition to control of high BP in those with established hypertension. Even partial improvement in the age-related increase in BP would eliminate a large proportion of the existing burden of BP-related CVD.

### Sources of Funding

P.K. Whelton was supported by a Centers for Research Excellence grant from the National Institute of General Medical Sciences (P20GM109036).

### Disclosures

None.

### References

1. Popper KR. *The Logic of Scientific Discovery*. London: Routledge; 1959.
2. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58:295–300.
3. Osler W. *The Principles and Practice of Medicine*. New York: D Appleton and Company; 1892.
4. Riva-Rocci S. Un nuovo sfigmomanometro. *Gazz Medi Torino*. 1896;50:981–996.
5. Korotkov NS. To the question of methods of determining the blood pressure. *Rep Imp Military Acad*. 1905;11:365–367.
6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for life insurance. *JAMA*. 1914;63:1752–1754.
7. Janeway TC. A clinical study of hypertensive cardiovascular disease. *Arch Intern Med*. 1913;12:755–758.
8. Lowenstein FW. Blood pressure in relation to age and sex in the tropics and subtropics. A review of the literature and an investigation in two tribes of Brazil Indians. *Lancet*. 1961;277:389–392.
9. Page LB, Damon A, Moellering RC Jr. Antecedents of cardiovascular disease in six Solomon Islands societies. *Circulation*. 1974;49:1132–1146. doi: 10.1161/01.cir.49.6.1132
10. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a “no-salt” culture. *Circulation*. 1975;52:146–151. doi: 10.1161/01.cir.52.1.146
11. Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers MP, Franco LJ, Marcopito LF, Spooner VJ, Dyer AR, Elliott P. Blood pressure in four remote populations in the INTERSALT Study. *Hypertension*. 1989;14:238–246. doi: 10.1161/01.hyp.14.3.238
12. National Academies of Sciences, Engineering, and Medicine 2019. *Dietary Reference Intakes for Sodium and Potassium*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25353>.
13. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:1269–1324. doi: 10.1161/HYP.0000000000000066
14. Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, Krumholz HM. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. *BMJ*. 2018;362:k2357. doi: 10.1136/bmj.k2357
15. NCD Risk Factor Collaboration (NCD-RisC). Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. *Int J Epidemiol*. 2018;47:872–883.
16. Keith NM, Wegener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. *Am J Sci*. 1939;197:332–343.
17. White P. *Heart Disease*. 2nd ed. New York: McMillan Co; 1937:326.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular

- mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–1913. DOI: 10.1016/S0140-6736(02)11911-8
19. Fuchs FD, ed. *Essentials of Hypertension*. Cham, Switzerland: Springer; 2018.
  20. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, Bartz TM, Santhanakrishnan R, Lee DS, Chan C, et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. *Circ Heart Fail*. 2016;9:003026. doi: 10.1161/CIRCHEARTFAILURE.115.003116
  21. Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, Rahimi K. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. *Int J Epidemiol*. 2017;46:162–172. doi: 10.1093/ije/dyw053
  22. Rahimi K, Mohseni H, Kiran A, Tran J, Nazarzadeh M, Rahimian F, Woodward M, Dwyer T, MacMahon S, Otto CM. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. *Eur Heart J*. 2018;39:3596–3603. doi: 10.1093/eurheartj/ehy486
  23. Rahimi K, Mohseni H, Otto CM, Conrad N, Tran J, Nazarzadeh M, Woodward M, Dwyer T, MacMahon S. Elevated blood pressure and risk of mitral regurgitation: a longitudinal cohort study of 5.5 million United Kingdom adults. *PLoS Med*. 2017;14:e1002404. doi: 10.1371/journal.pmed.1002404
  24. Emdin CA, Anderson SG, Callender T, Conrad N, Salimi-Khorshidi G, Mohseni H, Woodward M, Rahimi K. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. *BMJ*. 2015;351:h4865. doi: 10.1136/bmj.h4865
  25. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. *Arch Intern Med*. 2005;165:923–928. doi: 10.1001/archinte.165.8.923
  26. Kanno A, Kikuya M, Ohkubo T, Hashimoto T, Satoh M, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, et al. Pre-hypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama Study. *Nephrol Dial Transplant*. 2012;27:3218–3223. doi: 10.1093/ndt/gfs054
  27. Emdin CA, Rothwell PM, Salimi-Khorshidi G, Kiran A, Conrad N, Callender T, Mehta Z, Pendlebury ST, Anderson SG, Mohseni H, et al. Blood pressure and risk of vascular dementia: evidence from a primary care registry and a Cohort Study of transient ischemic attack and stroke. *Stroke*. 2016;47:1429–1435. doi: 10.1161/STROKEAHA.116.012658
  28. Walker KA, Sharrett AR, Wu A, Schneider ALC, Albert M, Lutsey PL, Bandeen-Roche K, Coresh J, Gross AL, Windham BG, et al. Association of midlife to late-life blood pressure patterns with incident dementia. *JAMA*. 2019;322:535–545. doi: 10.1001/jama.2019.10575
  29. Joas E, Bäckman K, Gustafson D, Ostling S, Waern M, Guo X, Skoog I. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. *Hypertension*. 2012;59:796–801. doi: 10.1161/HYPERTENSIONAHA.111.182204
  30. Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of Prospective Studies. *J Am Coll Cardiol*. 2015;66:1552–1562. doi: 10.1016/j.jacc.2015.07.059
  31. Ning L, Yang L. Hypertension might be a risk factor for erectile dysfunction: a meta-analysis. *Andrologia*. 2017;49. doi: 10.1111/and.12644
  32. Chakravarthy U, Wong TY, Fletcher A, Pault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC Ophthalmol*. 2010;10:31. doi: 10.1186/1471-2415-10-31
  33. Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. *J Gerontol A Biol Sci Med Sci*. 2012;67:395–405. doi: 10.1093/gerona/glr223
  34. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo AP, Hering D, et al. A call to action and a life-course strategy to address the global burden of raised blood pressure on current and future generations: the lancet commission on hypertension. *Lancet*. 2016;388:2665–2712. doi: 10.1016/S0140-6736(16)31134-5
  35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. *JAMA*. 1967; 202:1028–1034.
  36. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA*. 1991; 265:3255–3264.
  37. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939
  38. Fuchs FD, Klag MJ, Whelton PK. The classics: a tribute to the fiftieth anniversary of the randomized clinical trial. *J Clin Epidemiol*. 2000;53:335–342. doi: 10.1016/S0895-4356(99)00185-7
  39. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. *JAMA*. 2016;315:2673–2682. doi: 10.1001/jama.2016.7050
  40. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665. doi: 10.1136/bmj.b1665
  41. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8
  42. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. *JAMA Cardiol*. 2017;2:775–781. doi: 10.1001/jamacardio.2017.1421
  43. Descartes R. *A Discourse on Method: Meditations and Principles*. Translated by Veitch, John. London: Orion Publishing Group, 2004.
  44. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA*. 2019;321:553–561. doi: 10.1001/jama.2018.21442
  45. Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, et al; The SPRINT MIND Investigators for the SPRINT Research Group. Association of intensive versus standard blood pressure control with cerebral white matter lesions. *JAMA*. 2019;322:524–534. doi: 10.1001/jama.2019.10551
  46. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, et al; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. *Circulation*. 2006;114:1028–1035. doi: 10.1161/CIRCULATIONAHA.106.636746
  47. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, et al; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med*. 2010;363:905–917. doi: 10.1056/NEJMoa1003114
  48. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357:2109–2122. doi: 10.1056/NEJMoa0706628
  49. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720
  50. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380:347–357. doi: 10.1056/NEJMoa1812389
  51. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bøhlhåvek J, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303

52. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. *Am J Cardiol*. 1976;37:269–282. doi: 10.1016/0002-9149(76)90323-4
53. World Health Organization. *The World Health Report 2002 - Reducing Risks, Promoting Healthy Life (Internet)*. Geneva: WHO; 2002. Available in: <http://www.who.int/whr/2002>. Accessed June 14, 2019.
54. Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. *Hypertension*. 2014;64:281–286. doi: 10.1161/HYPERTENSIONAHA.114.03292
55. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, Eguchi K, Kario K, Hoshida S, Polonia J, et al; ABC-H Investigators. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. *Hypertension*. 2016;67:693–700. doi: 10.1161/HYPERTENSIONAHA.115.06981
56. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet*. 2014;383:970–983. doi: 10.1016/S0140-6736(13)61836-X
57. Mallmann AB, Fuchs SC, Gus M, Fuchs FD, Moreira LB. Population-attributable risks for ischemic stroke in a community in South Brazil: a case-control study. *PLoS One*. 2012;7:e35680. doi: 10.1371/journal.pone.0035680
58. Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. *J Hum Hypertens*. 2008;22:48–50. doi: 10.1038/sj.jhh.1002252
59. Kurioka S, Horie S, Inoue A, Mafune K, Tsuda Y, Otsuji Y. Risk of progression to hypertension in nonhypertensive Japanese workers aged 20–64 years. *J Hypertens*. 2014;32:236–244. doi: 10.1097/HJH.0000000000000031
60. Markus MR, Stritzke J, Lieb W, Mayer B, Luchner A, Döring A, Keil U, Hense HW, Schunkert H. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. *J Hypertens*. 2008;26:2040–2049. doi: 10.1097/HJH.0b013e328308da55
61. Santos AB, Gupta DK, Bello NA, Gori M, Claggett B, Fuchs FD, Shah AM, Coresh J, Sharrett AR, Cheng S, et al. Prehypertension is associated with abnormalities of cardiac structure and function in the atherosclerosis risk in communities Study. *Am J Hypertens*. 2016;29:568–574. doi: 10.1093/ajh/hpv156
62. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med*. 2006;354:1685–1697. doi: 10.1056/NEJMoa060838
63. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübecke C, Gansz A, et al; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. *J Hypertens*. 2008;26:1487–1496. doi: 10.1097/HJH.0b013e3282ff8864
64. Fuchs SC, Poli-de-Figueiredo Carlos E, Figueiredo-Neto JA, Scala LC, Whelton PK, Mosele F, de Mello RB, Vilela-Martin JF, Moreira LB, Chaves H, et al. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER-Prevention randomized clinical trial. *J Am Heart Assoc*. 2016;5:e004248. doi: 10.1161/JAHA.116.004248